Back to Stocks

KRMD

KORU Medical Systems, Inc.
7 filings tracked
healthcaremedical devicesSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

KORU Medical Systems is demonstrating a clear inflection point in its growth trajectory, reporting a 22.1% year-over-year increase in net revenues to $11.8 million for the first quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the top-line growth, KORU Medical faces concerning headwinds in its core unit economics. Gross margins contracted to 61.5% from 62.8% in the prior year, as the cost of goods sold grew at a faster rate than revenue.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every KRMD filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and persistent operational inefficiency. KORU's ability to grow its international footprint and penetrate the pharma services market is a powerful signal of product-market fit for the FREEDOM System. The narrowing of net losses suggests that the company is beginning to find a path toward operating leverage, provided it can stabilize its cost structure. However, the trade-off for this growth is a tightening of the balance sheet and a decline in gross margins. The recent credit facility amendment provides a necessary safety net, but the new liquidity covenants place a premium on the company's ability to achieve positive EBITDA quickly. Investors must weigh the impressive 22% revenue growth against the risks of leadership transition and the volatility of clinical trial-based revenue streams to determine if the scaling narrative is sustainable.

Selected Quarter

Core Takeaway

KORU is successfully growing its market share in SCIg delivery, but must stabilize gross margins and leadership to reach sustainable profitability.

Investor Lens

The critical trade-off is between the impressive revenue growth rate and the deteriorating gross margin profile.

Watch Next

The transition to a new CEO and the achievement of positive Adjusted EBITDA to satisfy new credit covenants.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.05Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Net revenues grew 22.1% year-over-year to $11.8 million.

earnings beat
70%
bearishMay 6

Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.

margin compression
40%
bearishMay 6

CEO Linda Tharby announced retirement and transition to advisory role.

management change
60%
bullishMay 6

Amended credit facility extends maturities and lowers interest rate floor.

debt restructure
50%
bullishMay 6

Net revenues grew 22.1% year-over-year to $11.8 million.

earnings beat
70%
bearishMay 6

Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.

margin compression
40%
bearishMay 6

CEO Linda Tharby announced retirement and transition to advisory role.

management change
60%
bullishMay 6

Amended credit facility extends maturities and lowers interest rate floor.

debt restructure
50%
bullishMay 6

Net revenues grew 22.1% year-over-year to $11.8 million.

earnings beat
70%
bearishMay 6

Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.

margin compression
40%
bearishMay 6

CEO Linda Tharby announced retirement and transition to advisory role.

management change
60%
bullishMay 6

Amended credit facility extends maturities and lowers interest rate floor.

debt restructure
50%
bullishMay 6

Net revenues grew 22.1% year-over-year to $11.8 million.

earnings beat
70%
bearishMay 6

Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.

margin compression
40%
bearishMay 6

CEO Linda Tharby announced retirement and transition to advisory role.

management change
60%
bullishMay 6

Amended credit facility extends maturities and lowers interest rate floor.

debt restructure
50%
bullishMay 6

Net revenues grew 22.1% year-over-year to $11.8 million.

earnings beat
70%
bearishMay 6

Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.

margin compression
40%
bearishMay 6

CEO Linda Tharby announced retirement and transition to advisory role.

management change
60%
bullishMay 6

Amended credit facility extends maturities and lowers interest rate floor.

debt restructure
50%
bullishMay 6

Net revenues grew 22.1% year-over-year to $11.8 million.

earnings beat
70%
bearishMay 6

Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.

margin compression
40%
bearishMay 6

CEO Linda Tharby announced retirement and transition to advisory role.

management change
60%
bullishMay 6

Amended credit facility extends maturities and lowers interest rate floor.

debt restructure
50%
bullishMay 6

Net revenues grew 22.1% year-over-year to $11.8 million.

earnings beat
70%
bearishMay 6

Gross margin declined from 62.8% to 61.5% due to production costs and tariffs.

margin compression
40%
bearishMay 6

CEO Linda Tharby announced retirement and transition to advisory role.

management change
60%
bullishMay 6

Amended credit facility extends maturities and lowers interest rate floor.

debt restructure
50%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and persistent operational inefficiency. KORU's ability to grow its international footprint and penetrate the pharma services market is a powerful signal of product-market fit for the FREEDOM System. The narrowing of net losses suggests that the company is beginning to find a path toward operating leverage, provided it can stabilize its cost structure. However, the trade-off for this growth is a tightening of the balance sheet and a decline in gross margins. The recent credit facility amendment provides a necessary safety net, but the new liquidity covenants place a premium on the company's ability to achieve positive EBITDA quickly. Investors must weigh the impressive 22% revenue growth against the risks of leadership transition and the volatility of clinical trial-based revenue streams to determine if the scaling narrative is sustainable.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.